Off to the organelles - killing cancer cells with targeted gold nanoparticles

Theranostics

Volumn 5, Issue 4, 2015, Pages 357-370

  Kodiha, Mohamed ^a   Wang, Yi Meng ^a   Hutter, Eliza ^a   Maysinger, Dusica ^a   Stochaj, Ursula ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

AuNPs; Cancer cell imaging; Gold nanoparticles

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR; GLUCOCORTICOID RECEPTOR; GOLD NANOPARTICLE; MACROGOL; DRUG CARRIER; GOLD; NANOPARTICLE;

BIOENERGY; CANCER CELL; CELL DEATH; CELL GROWTH; CELL ORGANELLE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPORT; CELLULAR DISTRIBUTION; ELECTROMAGNETIC FIELD; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOSOME; EXTRACELLULAR MATRIX; GLYCOLYSIS; HUMAN; LIVER CELL CARCINOMA; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MOLECULAR DYNAMICS; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PROTEIN BINDING; PROTEIN MOTIF; REVIEW; RNA SYNTHESIS; CELL NUCLEUS; CHEMISTRY; DRUG THERAPY; MOLECULAR MEDICINE; NEOPLASMS; PHOTOTHERAPY; PROCEDURES; THERMOTHERAPY;

CELL NUCLEUS; DRUG CARRIERS; DRUG THERAPY; GOLD; HUMANS; HYPERTHERMIA, INDUCED; MITOCHONDRIA; MOLECULAR MEDICINE; NANOPARTICLES; NEOPLASMS; PHOTOTHERAPY;

EID: 84924325424     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10657     Document Type: Review

References (146)

1. Hanahan D, Weinberg Robert A. Hallmarks of cancer: The next generation. Cell. 2011; 144: 646-74.
2. Ubah OC, Wallace HM. Cancer therapy: Targeting mitochondria and other sub-cellular organelles. Curr Pharm Des. 2014; 20: 201-22.
3. Wright J. Nanotechnology: Deliver on a promise. Nature. 2014; 509: S58-S9.
4. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Del Rev. 2008; 60: 1307-15.
5. Hutter E, Maysinger D. Gold nanoparticles and quantum dots for bioimaging. Microsc Res Tech. 2011; 74: 592-604.
6. Hutter E, Maysinger D. Gold-nanoparticle-based biosensors for detection of enzyme activity. Trends Pharmacol Sci. 2013; 34: 497-507.
7. Zhao P, Li N, Astruc D. State of the art in gold nanoparticle synthesis. Coord Chem Rev. 2013; 257: 638-65.
8. Jana NR, Gearheart L, Murphy CJ. Wet chemical synthesis of high aspect ratio cylindrical gold nanorods. J Phys Chem B. 2001; 105: 4065-7.
9. Brown KR, Natan MJ. Hydroxylamine seeding of colloidal au nanoparticles in solution and on surfaces. Langmuir. 1998; 14: 726-8.
10. Nikoobakht B, El-Sayed MA. Preparation and growth mechanism of gold nanorods (NRs) using seed-mediated growth method. Chem Mater. 2003; 15: 1957-62.
11. Sapsford KE, Algar WR, Berti L, Gemmill KB, Casey BJ, Oh E, et al. Functionalizing nanoparticles with biological molecules: Developing chemistries that facilitate nanotechnology. Chem Rev. 2013; 113: 1904-2074.
12. Huefner A, Septiadi D, Wilts BD, Patel II, Kuan W-L, Fragniere A, et al. Gold nanoparticles explore cells: Cellular uptake and their use as intracellular probes. Methods. 2014; 68: 354-63.
13. Dykman LA, Khlebtsov NG. Uptake of engineered gold nanoparticles into mammalian cells. Chem Rev. 2014; 114: 1258-88.
14. Lévy R, Shaheen U, Cesbron Y, Sée V. Gold nanoparticles delivery in mammalian live cells: A critical review. Nano Reviews. 2010; 1: 10.3402/nano.v1i0.4889.
15. Jeremic B, Aguerri AR, Filipovic N. Radiosensitization by gold nanoparticles. Clin Translat Oncol. 2013; 15: 593-601.
16. Jain S, Hirst DG, O'Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012; 85: 101-13.
17. Ahmad MZ, Akhter S, Rahman Z, Akhter S, Anwar M, Mallik N, et al. Nanometric gold in cancer nanotechnology: Current status and future prospect. J Pharm Pharmacol. 2013; 65: 634-51.
18. Dreaden EC, Austin LA, Mackey MA, El-Sayed MA. Size matters: Gold nanoparticles in targeted cancer drug delivery. Ther Deliv. 2012; 3: 457-78.
19. Holback H, Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res. 2011; 28: 1819-30.
20. Leung J, Wu S, Chou K, Signorell R. Investigation of sub-100 nm gold nanoparticles for laser-induced thermotherapy of cancer. Nanomaterials. 2013; 3: 86-106.
21. [Internet] NIH: Clinical trials. 2014. http://clinicaltrials.gov/
22. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Gannon WE, Walker M, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. 2010; 16: 6139-49.
23. Alexander CM, Hamner KL, Maye MM, Dabrowiak JC. Multifunctional DNA-gold nanoparticles for targeted doxorubicin delivery. Bioconjug Chem. 2014.
24. Park H, Tsutsumi H, Mihara H. Cell-selective intracellular drug delivery using doxorubicin and a-helical peptides conjugated to gold nanoparticles. Biomaterials. 2014; 35: 3480-7.
25. Sakhrani NM, Padh H. Organelle targeting: Third level of drug targeting. Drug Des Devel Ther. 2013; 7: 585-99.
26. Yuan H, Fales AM, Vo-Dinh T. Tat peptide-functionalized gold nanostars: Enhanced intracellular delivery and efficient nir photothermal therapy using ultralow irradiance. J Am Chem Soc. 2012; 134: 11358-61.
27. Kong T, Zeng J, Wang X, Yang X, Yang J, McQuarrie S, et al. Enhancement of radiation cytotoxicity in breast-cancer cells by localized attachment of gold nanoparticles. Small. 2008; 4: 1537-43.
28. Brown SD, Nativo P, Smith J-A, Stirling D, Edwards PR, Venugopal B, et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010; 132: 4678-84.
29. Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, et al. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2013; 13: 239-46.e1.
30. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012; 291: 1-9.
31. Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther. 2014; 7: 1015-23.
32. Mackey MA, Saira F, Mahmoud MA, El-Sayed MA. Inducing cancer cell death by targeting its nucleus: Solid gold nanospheres versus hollow gold nanocages. Bioconjug Chem. 2013; 24: 897-906.
33. Chen W-H, Chen J-X, Cheng H, Chen C-S, Yang J, Xu X-D, et al. A new anti- cancer strategy of damaging mitochondria by pro-apoptotic peptide functionalized gold nanoparticles. Chem Commun (Camb). 2013; 49: 6403-5.
34. Wang F, Wang Y-C, Dou S, Xiong M-H, Sun T-M, Wang J. Doxorubicin- tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano. 2011; 5: 3679-92.
35. Gibson JD, Khanal BP, Zubarev ER. Paclitaxel-functionalized gold nanoparticles. J Am Chem Soc. 2007; 129: 11653-61.
36. Kumar A, Huo S, Zhang X, Liu J, Tan A, Li S, et al. Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(IV) drug for prostate cancer treatment. ACS Nano. 2014; 8: 4205-20.
37. Chen H, Zhang X, Dai S, Ma Y, Cui S, Achilefu S, et al. Multifunctional gold nanostar conjugates for tumor imaging and combined photothermal and chemo-therapy. Theranostics. 2013; 3: 633-49.
38. Almeida JPM, Figueroa ER, Drezek RA. Gold nanoparticle mediated cancer immunotherapy. Nanomed Nanotechnol Biol Med. 2014; 10: 503-14.
39. Tkachenko AG, Xie H, Coleman D, Glomm W, Ryan J, Anderson MF, et al. Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc. 2003; 125: 4700-1.
40. Akhter S, Ahmad MZ, Ahmad FJ, Storm G, Kok RJ. Gold nanoparticles in theranostic oncology: Current state-of-the-art. Expert Opin Drug Deliv. 2012; 9: 1225-43.
41. Murphy CJ, Gole AM, Stone JW, Sisco PN, Alkilany AM, Goldsmith EC, et al. Gold nanoparticles in biology: Beyond toxicity to cellular imaging. Acc Chem Res. 2008; 41: 1721-30.
42. Dreaden EC, El-Sayed MA. Detecting and destroying cancer cells in more than one way with noble metals and different confinement properties on the nanoscale. Acc Chem Res. 2012; 45: 1854-65.
43. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010; 6: 12-21.
44. Llevot A, Astruc D. Applications of vectorized gold nanoparticles to the diagnosis and therapy of cancer. Chem Soc Rev. 2012; 41: 242-57.
45. Cho EC, Xie J, Wurm PA, Xia Y. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Lett. 2009; 9: 1080-4.
46. Kodiha M, Hutter E, Boridy S, Juhas M, Maysinger D, Stochaj U. Gold nanoparticles induce nuclear damage in breast cancer cells which is further amplified by hyperthermia. Cell Mol Life Sci. 2014; 71: 4259-73.
47. Wang L, Liu Y, Li W, Jiang X, Ji Y, Wu X, et al. Selective targeting of gold nanorods at the mitochondria of cancer cells: Implications for cancer therapy. Nano Lett. 2010; 11: 772-80.
48. Tkachenko AG, Xie H, Liu YL, Coleman D, Ryan J, Glomm WR, et al. Cellular trajectories of peptide-modified gold particle complexes: Comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem. 2004; 15: 482-90.
49. Chithrani BD, Ghazani AA, Chan WCW. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006; 6: 662-8.
50. Chithrani BD, Chan WCW. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 2007; 7: 1542-50.
51. Mandal D, Maran A, Yaszemski M, Bolander M, Sarkar G. Cellular uptake of gold nanoparticles directly cross-linked with carrier peptides by osteosarcoma cells. J Mater Sci Mater Med. 2009; 20: 347-50.
52. Sun L, Liu D, Wang Z. Functional gold nanoparticle-peptide complexes as cell-targeting agents. Langmuir. 2008; 24: 10293-7.
53. Dekiwadia CD, Lawrie AC, Fecondo JV. Peptide-mediated cell penetration and targeted delivery of gold nanoparticles into lysosomes. J Pept Sci. 2012; 18: 527-34.
54. Song J, Zhou J, Duan H. Self-assembled plasmonic vesicles of sers-encoded amphiphilic gold nanoparticles for cancer cell targeting and traceable intracellular drug delivery. J Am Chem Soc. 2012; 134: 13458-69.
55. Dam DHM, Lee JH, Sisco PN, Co DT, Zhang M, Wasielewski MR, et al. Direct observation of nanoparticle-cancer cell nucleus interactions. ACS Nano. 2012; 6: 3318-26.
56. Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J Am Chem Soc. 2010; 132: 1517-9.
57. Shah NB, Dong J, Bischof JC. Cellular uptake and nanoscale localization of gold nanoparticles in cancer using label-free confocal raman microscopy. Mol Pharm. 2010; 8: 176-84.
58. Gu Y-J, Cheng J, Lin C-C, Lam YW, Cheng SH, Wong W-T. Nuclear penetration of surface functionalized gold nanoparticles. Toxicol Appl Pharmacol. 2009; 237: 196-204.
59. Ryan JA, Overton KW, Speight ME, Oldenburg CM, Loo L, Robarge W, et al. Cellular uptake of gold nanoparticles passivated with bsa-sv40 large t antigen conjugates. Anal Chem. 2007; 79: 9150-9.
60. Huo S, Jin S, Ma X, Xue X, Yang K, Kumar A, et al. Ultrasmall gold nanoparticles as carriers for nucleus-based gene therapy due to size-dependent nuclear entry. ACS Nano. 2014; 8: 5852-62.
61. de la Fuente JM, Berry CC. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem. 2005; 16: 1176-80.
62. Berry CC, de la Fuente JM, Mullin M, Chu SW, Curtis AS. Nuclear localization of HIV-1 tat functionalized gold nanoparticles. IEEE Trans Nanobioscience. 2007; 6: 262-9.
63. Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, Robertson JD, et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010; 10: 2543-8.
64. Ojea-Jimenez I, Garcia-Fernandez L, Lorenzo J, Puntes VF. Facile preparation of cationic gold nanoparticle-bioconjugates for cell penetration and nuclear targeting. ACS Nano. 2012; 6: 7692-702.
65. Chithrani BD, Stewart J, Allen C, Jaffray DA. Intracellular uptake, transport, and processing of nanostructures in cancer cells. Nanomed Nanotechnol Biol Med. 2009; 5: 118-27.
66. Nativo P, Prior IA, Brust M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano. 2008; 2: 1639-44.
67. Oyelere AK, Chen PC, Huang X, El-Sayed IH, El-Sayed MA. Peptide- conjugated gold nanorods for nuclear targeting. Bioconjug Chem. 2007; 18: 1490-7.
68. Yang C, Uertz J, Yohan D, Chithrani BD. Peptide modified gold nanoparticles for improved cellular uptake, nuclear transport, and intracellular retention. Nanoscale. 2014; 6: 12026-33.
69. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005; 1: 325-7.
70. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem. 2006; 17: 603-9.
71. Huff TB, Hansen MN, Zhao Y, Cheng J-X, Wei A. Controlling the cellular uptake of gold nanorods. Langmuir. 2007; 23: 1596-9.
72. Huff TB, Tong L, Zhao Y, Hansen MN, Cheng J-X, Wei A. Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine. 2007; 2: 125-32.
73. Bhattacharya R, Patra CR, Earl A, Wang S, Katarya A, Lu L, et al. Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells. Nanomed Nanotechnol Biol Med. 2007; 3: 224-38.
74. Shirazi AN, Tiwari RK, Oh D, Sullivan B, McCaffrey K, Mandal D, et al. Surface decorated gold nanoparticles by linear and cyclic peptides as molecular transporters. Mol Pharm. 2013; 10: 10.1021/mp400199e.
75. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: A microscopic overview. Langmuir. 2005; 21: 10644-54.
76. Chen Z, Zhang L, He Y, Li Y. Sandwich-type Au-PEI/DNA/PEI-Dexa nanocomplex for nucleus-targeted gene delivery in vitro and in vivo. ACS Appl Mater Interfaces. 2014; 6: 14196-206.
77. Han G, You C-C, Kim B-j, Turingan RS, Forbes NS, Martin CT, et al. Light-regulated release of DNA and its delivery to nuclei by means of photolabile gold nanoparticles. Angew Chem Int Ed Engl. 2006; 45: 3165-9.
78. El-Sayed IH, Huang X, El-Sayed MA. Surface plasmon resonance scattering and absorption of anti-egfr antibody conjugated gold nanoparticles in cancer diagnostics: Applications in oral cancer. Nano Lett. 2005; 5: 829-34.
79. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006; 128: 2115-20.
80. Hauck TS, Ghazani AA, Chan WCW. Assessing the effect of surface chemistry on gold nanorod uptake, toxicity, and gene expression in mammalian cells. Small. 2008; 4: 153-9.
81. Oh E, Delehanty JB, Sapsford KE, Susumu K, Goswami R, Blanco-Canosa JB, et al. Cellular uptake and fate of PEGylated gold nanoparticles is dependent on both cell-penetration peptides and particle size. ACS Nano. 2011; 5: 6434-48.
82. Liu X, Huang N, Li H, Jin Q, Ji J. Surface and size effects on cell interaction of gold nanoparticles with both phagocytic and nonphagocytic cells. Langmuir. 2013; 29: 9138-48.
83. Coradeghini R, Gioria S, García CP, Nativo P, Franchini F, Gilliland D, et al. Size-dependent toxicity and cell interaction mechanisms of gold nanoparticles on mouse fibroblasts. Toxicol Lett. 2013; 217: 205-16.
84. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, et al. Size-dependent cytotoxicity of gold nanoparticles. Small. 2007; 3: 1941-9.
85. Huang K, Ma H, Liu J, Huo S, Kumar A, Wei T, et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano. 2012; 6: 4483-93.
86. Salnikov V, Lukyanenko YO, Frederick CA, Lederer WJ, Lukyanenko V. Probing the outer mitochondrial membrane in cardiac mitochondria with nanoparticles. Biophys J. 2007; 92: 1058-71.
87. Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, et al. Mito-porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta. 2008; 1778: 423-32.
88. Wang L, Jiang X, Ji Y, Bai R, Zhao Y, Wu X, et al. Surface chemistry of gold nanorods: Origin of cell membrane damage and cytotoxicity. Nanoscale. 2013; 5: 8384-91.
89. Zhuang Q, Jia H, Du L, Li Y, Chen Z, Huang S, et al. Targeted surface- functionalized gold nanoclusters for mitochondrial imaging. Biosensors Bioelectron. 2014; 55: 76-82.
90. Mocan L, Ilie I, Tabaran FA, Dana B, Zaharie F, Zdrehus C, et al. Surface plasmon resonance-induced photoactivation of gold nanoparticles as mitochondria- targeted therapeutic agents for pancreatic cancer. Expert Opin Ther Targets. 2013; 17: 1383-93.
91. Marrache S, Dhar S. The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate. Chem Science. 2015. doi:10.1039/C4SC01963.
92. Cheng Y, Meyers JD, Agnes RS, Doane TL, Kenney ME, Broome A-M, et al. Addressing brain tumors with targeted gold nanoparticles: A new gold standard for hydrophobic drug delivery? Small. 2011; 7: 2301-6.
93. Scarì G, Porta F, Fascio U, Avvakumova S, Dal Santo V, De Simone M, et al. Gold nanoparticles capped by a gc-containing peptide functionalized with an rgd motif for integrin targeting. Bioconjug Chem. 2012; 23: 340-9.
94. de la Fuente JM, Berry CC, Riehle MO, Curtis ASG. Nanoparticle targeting at cells. Langmuir. 2006; 22: 3286-93.
95. Sykes EA, Chen J, Zheng G, Chan WCW. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano. 2014; 8: 5696-706.
96. Eghtedari M, Liopo AV, Copland JA, Oraevsky AA, Motamedi M. Engineering of hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer cells. Nano Lett. 2008; 9: 287-91.
97. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006; 239: 129-35.
98. de las Heras JI, Batrakou DG, Schirmer EC. Cancer biology and the nuclear envelope: A convoluted relationship. Semin Cancer Biol. 2013; 23: 125-37.
99. Jevtic P, Edens LJ, Vukovic LD, Levy DL. Sizing and shaping the nucleus: Mechanisms and significance. Curr Opin Cell Biol. 2014; 28: 16-27.
100. Matchett KB, McFarlane S, Hamilton SE, Eltuhamy YS, Davidson MA, Murray JT, et al. Ran GTPase in nuclear envelope formation and cancer metastasis. Adv Exp Med Biol. 2014; 773: 323-51.
101. Miyamoto Y, Loveland KL, Yoneda Y. Nuclear importin alpha and its physiological importance. Commun Integr Biol. 2012; 5: 220-2.
102. Quin JE, Devlin JR, Cameron D, Hannan KM, Pearson RB, Hannan RD. Targeting the nucleolus for cancer intervention. Biochim Biophys Acta. 2014; 1842: 802-16.
103. Ruggero D. Revisiting the nucleolus: From marker to dynamic integrator of cancer signaling. Sci Signal. 2012; 5: pe38.
104. Mor A, White MA, Fontoura BMA. Nuclear trafficking in health and disease. Curr Opin Cell Biol. 2014; 28: 28-35.
105. Kuusisto HV, Wagstaff KM, Alvisi G, Roth DM, Jans DA. Global enhancement of nuclear localization-dependent nuclear transport in transformed cells. FASEB J. 2012; 26: 1181-93.
106. Feldherr CM, Akin D. The permeability of the nuclear envelope in dividing and nondividing cell cultures. J Cell Biol. 1990; 111: 1-8.
107. Feldherr CM, Akin D. Signal-mediated nuclear transport in proliferating and growth-arrested BALB/c 3T3 cells. J Cell Biol. 1991; 115: 933-9.
108. Feldherr CM, Akin D. Regulation of nuclear transport in proliferating and quiescent cells. Exp Cell Res. 1993; 205: 179-86.
109. Tsoli M, Kuhn H, Brandau W, Esche H, Schmid G. Cellular uptake and toxicity of Au55 clusters. Small. 2005; 1: 841-4.
110. Panté N, Kann M. Nuclear pore complex is able to transport macromolecules with diameters of ~39 nm. Mol Biol Cell. 2002; 13: 425-34.
111. Feldherr CM, Akin D, Cohen RJ. Regulation of functional nuclear pore size in fibroblasts. J Cell Sci. 2001; 114: 4621-7.
112. Feldherr CM, Akin D. The location of the transport gate in the nuclear pore complex. J Cell Sci. 1997; 110: 3065-70.
113. Novak JP, Nickerson C, Franzen S, Feldheim DL. Purification of molecularly bridged metal nanoparticle arrays by centrifugation and size exclusion chromatography. Anal Chem. 2001; 73: 5758-61.
114. Krpetic Ž, Saleemi S, Prior IA, Sée V, Qureshi R, Brust M. Negotiation of intracellular membrane barriers by TAT-modified gold nanoparticles. ACS Nano. 2011; 5: 5195-201.
115. Tsai TL, Hou CC, Wang HC, Yang ZS, Yeh CS, Shieh DB, et al. Nucleocytoplasmic transport blockage by SV40 peptide-modified gold nanoparticles induces cellular autophagy. Int J Nanomedicine. 2012; 7: 5215-34.
116. Huschka R, Barhoumi A, Liu Q, Roth JA, Ji L, Halas NJ. Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano. 2012; 6: 7681-91.
117. Ryou S-M, Park M, Kim J-M, Jeon CO, Yun C-H, Han SH, et al. Inhibition of xenograft tumor growth in mice by gold nanoparticle-assisted delivery of short hairpin RNAs against Mcl-1L. J Biotechnol. 2011; 156: 89-94.
118. Kim J-H, Jang HH, Ryou S-M, Kim S, Bae J, Lee K, et al. A functionalized gold nanoparticles-assisted universal carrier for antisense DNA. Chem Commun (Camb). 2010; 46: 4151-3.
119. Kim D-W, Kim J-H, Park M, Yeom J-H, Go H, Kim S, et al. Modulation of biological processes in the nucleus by delivery of DNA oligonucleotides conjugated with gold nanoparticles. Biomaterials. 2011; 32: 2593-604.
120. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet. 2005; 39: 359-407.
121. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Del Rev. 2009; 61: 1250-75.
122. Wen S, Zhu D, Huang P. Targeting cancer cell mitochondria as a therapeutic approach. Future Med Chem. 2012; 5: 53-67.
123. Rehling P, Model K, Brandner K, Kovermann P, Sickmann A, Meyer HE, et al. Protein insertion into the mitochondrial inner membrane by a twin-pore translocase. Science. 2003; 299: 1747-51.
124. Szabo I, Zoratti M. Mitochondrial channels: Ion fluxes and more. Physiol Rev. 2014; 94: 519-608.
125. Smith RA, Hartley RC, Murphy MP. Mitochondria-targeted small molecule therapeutics and probes. Antioxid Redox Signal. 2011; 15: 3021-38.
126. Clarke Hanna J, Chambers Joseph E, Liniker E, Marciniak Stefan J. Endoplasmic reticulum stress in malignancy. Cancer Cell. 2014; 25: 563-73.
127. Chang M-Y, Shiau A-L, Chen Y-H, Chang C-J, Chen HHW, Wu C-L. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci. 2008; 99: 1479-84.
128. Khan JA, Pillai B, Das TK, Singh Y, Maiti S. Molecular effects of uptake of gold nanoparticles in HeLa cells. ChemBioChem. 2007; 8: 1237-40.
129. Cho W-S, Cho M, Jeong J, Choi M, Cho H-Y, Han BS, et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol. 2009; 236: 16-24.
130. Tsai Y-Y, Huang Y-H, Chao Y-L, Hu K-Y, Chin L-T, Chou S-H, et al. Identification of the nanogold particle-induced endoplasmic reticulum stress by omic techniques and systems biology analysis. ACS Nano. 2011; 5: 9354-69.
131. Kim CS, Le NDB, Xing Y, Yan B, Tonga GY, Kim C, et al. The role of surface functionality in nanoparticle exocytosis. Adv Healthc Mater. 2014; 3: 1200-2.
132. Oh N, Park J-H. Surface chemistry of gold nanoparticles mediates their exocytosis in macrophages. ACS Nano. 2014; 8: 6232-41.
133. Simpson CA, Salleng KJ, Cliffel DE, Feldheim DL. In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. Nanomedicine. 2013; 9: 257-63.
134. Jones SW, Roberts RA, Robbins GR, Perry JL, Kai MP, Chen K, et al. Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. J Clin Invest. 2013; 123: 3061-73.
135. van der Watt PJ, Stowell CL, Leaner VD. The nuclear import receptor kpnb1 and its potential as an anticancer therapeutic target. Crit Rev Eukaryot Gene Expr. 2013; 23: 1-10.
136. Christiansen A, Dyrskjøt L. The functional role of the novel biomarker karyopherin a 2 (KPNA2) in cancer. Cancer Lett. 2013; 331: 18-23.
137. Fan H, Lu Y, Qin H, Zhou Y, Gu Y, Zhou J, et al. High ran level is correlated with poor prognosis in patients with colorectal cancer. Int J Clin Oncol. 2013; 18: 856-63.
138. Truant R, Cullen BR. The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin ß-dependent nuclear localization signals. Mol Cell Biol. 1999; 19: 1210-7.
139. Ori A, Banterle N, Iskar M, Andrés-Pons A, Escher C, Khanh Bui H, et al. Cell type-specific nuclear pores: A case in point for context-dependent stoichiometry of molecular machines. Mol Syst Biol. 2013; 9:648.
140. Krpetic Z, Nativo P, See V, Prior IA, Brust M, Volk M. Inflicting controlled nonthermal damage to subcellular structures by laser-activated gold nanoparticles. Nano Lett. 2010; 10: 4549-54.
141. Neuberg P, Kichler A. Recent developments in nucleic acid delivery with polyethylenimines. Adv Genet. 2014; 88: 263-88.
142. Sheftel AD, Zhang AS, Brown C, Shirihai OS, Ponka P. Direct interorganellar transfer of iron from endosome to mitochondrion. Blood. 2007; 110: 125-32.
143. Huo S, Ma H, Huang K, Liu J, Wei T, Jin S, et al. Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res. 2013; 73: 319-30.
144. Lin M, Guo C, Li J, Zhou D, Liu K, Zhang X, et al. Polypyrrole-coated chainlike gold nanoparticle architectures with the 808 nm photothermal transduction efficiency up to 70%. ACS Appl Mater Interfaces. 2014; 6: 5860-8.
145. Song J, Fang Z, Wang C, Zhou J, Duan B, Pu L, et al. Photolabile plasmonic vesicles assembled from amphiphilic gold nanoparticles for remote-controlled traceable drug delivery. Nanoscale. 2013; 5: 5816-24.
146. Kanaras AG, Wang Z, Brust M, Cosstick R, Bates AD. Enzymatic disassembly of DNA-gold nanostructures. Small. 2007; 3: 590-4.